Integra LifeSciences Holdings Corporation (IART) Position Decreased by State of Wisconsin Investment Board

State of Wisconsin Investment Board reduced its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 7.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 278,100 shares of the life sciences company’s stock after selling 22,500 shares during the period. State of Wisconsin Investment Board owned 0.36% of Integra LifeSciences Holdings Corporation worth $15,159,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. FMR LLC raised its position in Integra LifeSciences Holdings Corporation by 44.1% in the first quarter. FMR LLC now owns 7,615,884 shares of the life sciences company’s stock worth $320,857,000 after buying an additional 2,329,710 shares during the period. BlackRock Inc. raised its position in Integra LifeSciences Holdings Corporation by 307,726.8% in the first quarter. BlackRock Inc. now owns 7,455,564 shares of the life sciences company’s stock worth $314,104,000 after buying an additional 7,453,142 shares during the period. Vanguard Group Inc. raised its position in Integra LifeSciences Holdings Corporation by 116.7% in the first quarter. Vanguard Group Inc. now owns 5,656,048 shares of the life sciences company’s stock worth $238,289,000 after buying an additional 3,046,488 shares during the period. Champlain Investment Partners LLC raised its position in Integra LifeSciences Holdings Corporation by 125.2% in the first quarter. Champlain Investment Partners LLC now owns 4,438,760 shares of the life sciences company’s stock worth $187,005,000 after buying an additional 2,468,145 shares during the period. Finally, Wells Fargo & Company MN raised its position in Integra LifeSciences Holdings Corporation by 18.0% in the first quarter. Wells Fargo & Company MN now owns 2,467,892 shares of the life sciences company’s stock worth $103,972,000 after buying an additional 375,857 shares during the period. Institutional investors and hedge funds own 85.66% of the company’s stock.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ IART) opened at 50.22 on Monday. Integra LifeSciences Holdings Corporation has a 12 month low of $37.71 and a 12 month high of $56.42. The firm has a market capitalization of $3.92 billion, a price-to-earnings ratio of 61.24 and a beta of 0.73. The firm’s 50-day moving average price is $52.04 and its 200-day moving average price is $47.26.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The company had revenue of $282.16 million during the quarter, compared to the consensus estimate of $283.58 million. During the same period in the prior year, the company earned $0.40 earnings per share. The company’s revenue for the quarter was up 13.2% compared to the same quarter last year. On average, equities analysts anticipate that Integra LifeSciences Holdings Corporation will post $1.90 earnings per share for the current year.

WARNING: This report was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://sportsperspectives.com/2017/08/21/integra-lifesciences-holdings-corporation-iart-position-decreased-by-state-of-wisconsin-investment-board.html.

IART has been the subject of a number of recent analyst reports. Oppenheimer Holdings, Inc. set a $54.00 price target on Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research report on Monday, May 15th. Jefferies Group LLC increased their price target on Integra LifeSciences Holdings Corporation from $52.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, May 31st. ValuEngine lowered Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $48.00 price target (up previously from $46.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, May 2nd. Finally, Cantor Fitzgerald initiated coverage on Integra LifeSciences Holdings Corporation in a research report on Thursday, June 29th. They issued an “overweight” rating and a $65.00 price target for the company. Five analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $52.63.

In other news, Director Donald E. Morel, Jr. acquired 10,000 shares of Integra LifeSciences Holdings Corporation stock in a transaction dated Friday, August 4th. The stock was bought at an average cost of $49.25 per share, with a total value of $492,500.00. Following the completion of the transaction, the director now directly owns 29,612 shares of the company’s stock, valued at $1,458,391. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Barbara B. Hill acquired 5,050 shares of Integra LifeSciences Holdings Corporation stock in a transaction dated Tuesday, August 1st. The shares were purchased at an average cost of $49.33 per share, with a total value of $249,116.50. Following the completion of the transaction, the director now directly owns 44,772 shares of the company’s stock, valued at $2,208,602.76. The disclosure for this purchase can be found here. Insiders acquired 17,550 shares of company stock valued at $864,842 over the last 90 days. Corporate insiders own 21.50% of the company’s stock.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply